Skip to content
OpenCapital
Get started

Sana Biotechnology SANA Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$15M—
Beam Therapeutics logo
Beam TherapeuticsBEAM
——
Artivion logo
ArtivionAORT
——

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+54.1%
Enterprise value$904.32M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's contingent consideration fair value adjustments?
Sana Biotechnology (SANA) reported contingent consideration fair value adjustments of $10.75M in Q1 2026.
How has Sana Biotechnology's contingent consideration fair value adjustments changed year-over-year?
Sana Biotechnology's contingent consideration fair value adjustments increased by 476.4% year-over-year, from $1.86M to $10.75M.